ASO vs QURE: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ASO and QURE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ASO and QURE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Academy Sports and Outdoors is one of the largest sporting goods and outdoor recreation retailers in the United States, operating large-format stores concentrated across Texas and the broader South and Southeast. Its assortment spans apparel, footwear, team and individual sports equipment, hunting, fishing, camping and other outdoor gear, plus patio, grills and outdoor-living goods, all merchandised around a value, everyday-low-price positioning that aims to undercut specialty rivals. A meaningful share of sales comes from a portfolio of private-label brands such as Magellan Outdoors, BCG, Game Winner and Freely, which the company reports made up roughly a fifth of merchandise sales in fiscal 2025 and which typically carry better margins than national brands.

Full ASO guide

uniQure N.V. is a Netherlands-based, Nasdaq-listed clinical-stage biotech developing adeno-associated virus (AAV) gene therapies for serious central-nervous-system and other genetic diseases. Its lead program is AMT-130, a one-time gene therapy for Huntington's disease, delivered surgically into the brain, that met its primary endpoint at three years with roughly 75% slowing of disease progression versus external controls in a Phase I/II study (an updated analysis put the 36-month slowing at about 80% on cUHDRS). The rest of the pipeline is earlier stage: AMT-162 for SOD1 ALS, AMT-260 for refractory mesial temporal lobe epilepsy, and AMT-191 for Fabry disease. The company already validated its platform once by developing Hemgenix, the hemophilia B gene therapy now commercialized by CSL Behring, which produces royalty income.

Full QURE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ASO drivers: New-store expansion beyond the South; Private-label brands and margin mix.
• QURE drivers: AMT-130 accelerated-approval review; First-mover position in Huntington's.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is discretionary-spending cyclicality: Academy sells goods consumers can delay buying, so a weaker labor market, inflation in essentials, or lower confidence can pressure comparable sales and margins quickly. For QURE, uniQure is a single-asset biotech, so any negative surprise on AMT-130, whether a Complete Response Letter, a request for a controlled confirmatory trial before approval, manufacturing questions, or safety concerns from an invasive brain-delivery procedure, could sharply reduce the company's value.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ASO if you believe its drivers more; QURE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ASO and QURE guides.

ASO. Academy still trades at a low earnings multiple, about 10x trailing and 8.4x forward, and about 0.6x sales, even after a 23% one-month rise. Part of the latest earnings jump came from non-recurring tariff refunds, so the forward multiple depends on margins holding near the guided 35.5% to 36.0% gross level. The next report is expected around December 8, 2026, with consensus near $1.33 of EPS on $1.44 billion of revenue.

QURE. uniQure is pre-profit, so traditional valuation multiples like P/E do not apply and the stock is valued on the probability-weighted potential of AMT-130, which the market sharply marked down after the September 2026 four-year data. Revenue is minimal, mostly Hemgenix royalties and license deals, while losses run near $250 million a year. Analysts' mean target was about $61 across 12 analysts in October 2026, far above the share price, a gap that shows how much depends on the FDA outcome.

Headline figures (approximate, October 2026): ASO shows revenue (ttm) ~$6.2 billion; Q2 fiscal 2026 ~$1.65 billion, up 3% (comps down 0.4%), q2 fiscal 2026 eps $2.31 adjusted vs ~$2.08 consensus, up ~19%, margins Q2 gross margin 40.4% (incl. ~510 bp of tariff refunds); FY guide 35.5% to 36.0%, net income (ttm) ~$396 million; ~6.4% net margin; QURE shows revenue (ttm) ~$18.7 million (Q2 2026 ~$5.1 million, mostly license and royalty), net loss (ttm) ~$252 million (Q2 2026 ~$71 million, EPS ~-$1.07 vs ~-$0.71 expected), cash vs debt ~$810 million cash, ~$552 million debt (June 30, 2026), share price ~$22.07 (October 16, 2026; YTD ~-5.6%, 1 year ~-63%).

ASO and QURE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ASO and QURE exposure against your real portfolio. It is not an investment adviser.